Literature DB >> 35445357

Is Prophylactic Cervical Drainage Effective in Patients Undergoing McKeown Esophagectomy Reconstructed Through the Retrosternal Route with Two-Field Lymphadenectomy?

Daisuke Fujiwara1, Masayuki Watanabe2, Yasukazu Kanie1, Suguru Maruyama1, Kei Sakamoto1, Akihiko Okamura1, Jun Kanamori1, Yu Imamura1, Shinji Mine1,3.   

Abstract

BACKGROUND: McKeown esophagectomy with two-field lymphadenectomy is the treatment of choice for oncologic esophagectomy. A cervical drain is placed in cases after modern two-field lymph node dissection (M2FD) to provide information on anastomotic leakage. However, the necessity of prophylactic cervical drainage during surgery remains unknown. This study aimed to clarify the clinical significance of cervical drainage in patients who underwent McKeown esophagectomy with M2FD.
METHODS: A total of 293 patients underwent McKeown surgery with two-field lymphadenectomy at our institute between January 2013 and December 2019. We compared the day of drain removal, amount of drainage volume, and the appearance of drainage fluid between patients with and without anastomotic leakage.
RESULTS: McKeown esophagectomy reconstructed through the retrosternal route is 203 patients (69.3%) of all. Nineteen patients (6.5%) experienced anastomotic leakage. The amount of cervical drain discharge was comparable between patients with and without anastomotic leakage. In addition, no purulent or salivary discharge was observed in patients with anastomotic leakage. There was no difference in the median day of drain removal between the groups. The initial clinical findings for the diagnosis of anastomotic leakage were surgical site infection in 10 (52.6%), fever in 5 (26.3%), prolonged inflammation in a blood test in 3 (15.8%), and bloody discharge from the chest tube in 1 (5.3%). There was no mortality due to any cause.
CONCLUSION: A prophylactic cervical drain may not be mandatory in patients with esophageal cancer undergoing McKeown esophagectomy reconstructed through the retrosternal route with two-field lymphadenectomy.
© 2022. The Author(s) under exclusive licence to Société Internationale de Chirurgie.

Entities:  

Mesh:

Year:  2022        PMID: 35445357     DOI: 10.1007/s00268-022-06578-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.282


  36 in total

1.  Total three-stage oesophagectomy for cancer of the oesophagus.

Authors:  K C McKeown
Journal:  Br J Surg       Date:  1976-04       Impact factor: 6.939

Review 2.  Recent progress in perioperative management of patients undergoing esophagectomy for esophageal cancer.

Authors:  Masayuki Watanabe; Akihiko Okamura; Tasuku Toihata; Kotaro Yamashita; Masami Yuda; Masaru Hayami; Ian Fukudome; Yu Imamura; Shinji Mine
Journal:  Esophagus       Date:  2018-04-25       Impact factor: 4.230

3.  Outcomes of extended lymph node dissection for squamous cell carcinoma of the thoracic esophagus.

Authors:  M Tsurumaru; Y Kajiyama; H Udagawa; H Akiyama
Journal:  Ann Thorac Cardiovasc Surg       Date:  2001-12       Impact factor: 1.520

4.  A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).

Authors:  Nobutoshi Ando; Hoichi Kato; Hiroyasu Igaki; Masayuki Shinoda; Soji Ozawa; Hideaki Shimizu; Tsutomu Nakamura; Hiroshi Yabusaki; Norio Aoyama; Akira Kurita; Kenichiro Ikeda; Tatsuo Kanda; Toshimasa Tsujinaka; Kenichi Nakamura; Haruhiko Fukuda
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

5.  Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy.

Authors:  Hiromasa Fujita; Susumu Sueyoshi; Toshiaki Tanaka; Teruhiko Fujii; Uhi Toh; Takashi Mine; Hiroko Sasahara; Tomoya Sudo; Satoru Matono; Hideaki Yamana; Kazuo Shirouzu
Journal:  World J Surg       Date:  2003-04-28       Impact factor: 3.352

Review 6.  Oesophageal cancer.

Authors:  Jesper Lagergren; Elizabeth Smyth; David Cunningham; Pernilla Lagergren
Journal:  Lancet       Date:  2017-06-22       Impact factor: 79.321

7.  Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.

Authors:  A Tsuburaya; J Mizusawa; Y Tanaka; N Fukushima; A Nashimoto; M Sasako
Journal:  Br J Surg       Date:  2014-03-25       Impact factor: 6.939

8.  Impact of thoracic recurrent laryngeal node dissection: 508 patients with tri-incisional esophagectomy.

Authors:  Zihui Tan; Guowei Ma; Jinming Zhao; Amos Ela Bella; Tiehua Rong; Jianhua Fu; Yuqi Meng; Kongjia Luo; Dongrong Situ; Peng Lin
Journal:  J Gastrointest Surg       Date:  2013-11-16       Impact factor: 3.452

9.  Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1.

Authors:  Yuko Kitagawa; Takashi Uno; Tsuneo Oyama; Ken Kato; Hiroyuki Kato; Hirofumi Kawakubo; Osamu Kawamura; Motoyasu Kusano; Hiroyuki Kuwano; Hiroya Takeuchi; Yasushi Toh; Yuichiro Doki; Yoshio Naomoto; Kenji Nemoto; Eisuke Booka; Hisahiro Matsubara; Tatsuya Miyazaki; Manabu Muto; Akio Yanagisawa; Masahiro Yoshida
Journal:  Esophagus       Date:  2018-08-31       Impact factor: 3.671

10.  Future Perspectives of Surgery for Esophageal Cancer.

Authors:  Hirotoshi Kikuchi; Hiroya Takeuchi
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-06-29       Impact factor: 1.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.